{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:25:55Z","timestamp":1787016355515,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1124\/jpet.107.123729","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T20:48:50Z","timestamp":1180644530000},"page":"1315-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacological Properties of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3 H)-one (TZB-30878), a Novel Therapeutic Agent for Diarrhea-Predominant Irritable Bowel Syndrome (IBS) and Its Effects on an Experimental IBS Model"],"prefix":"10.1016","volume":"322","author":[{"given":"Satoru","family":"Tamaoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinao","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Asagarasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michitaka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.123729_bib1","doi-asserted-by":"crossref","unstructured":"Butler A, Elswood CJ, Burridge J, Ireland SJ, Bunce KT, Kilpatrick GJ, and Tyers MB (1990) The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues. Br J Pharmacol 101: 591\u2013598.","DOI":"10.1111\/j.1476-5381.1990.tb14126.x"},{"key":"10.1124\/jpet.107.123729_bib2","doi-asserted-by":"crossref","unstructured":"Camilleri M and Choi M-G (1997) Review article: irritable bowel syndrome. Aliment Pharmacol Ther 11: 3\u201315.","DOI":"10.1046\/j.1365-2036.1997.84256000.x"},{"key":"10.1124\/jpet.107.123729_bib3","doi-asserted-by":"crossref","unstructured":"Camilleri M, Chey W, Mayer E, Northcutt A, Heath A, Dukes G, McSorley D, and Mangel A (2001) A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with d-IBS. Arch Intern Med 161: 1733\u20131740.","DOI":"10.1001\/archinte.161.14.1733"},{"key":"10.1124\/jpet.107.123729_bib4","doi-asserted-by":"crossref","unstructured":"Camilleri M, Northcutt AR, Kong S, Duke G, McSorley D, and Mangel A (2000) The efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 355: 1035\u20131040.","DOI":"10.1016\/S0140-6736(00)02033-X"},{"key":"10.1124\/jpet.107.123729_bib5","doi-asserted-by":"crossref","unstructured":"Cann PA, Read NW, Brown C, Hobson N, and Holdsworth CD (1983) Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 24: 405\u2013411.","DOI":"10.1136\/gut.24.5.405"},{"key":"10.1124\/jpet.107.123729_bib6","doi-asserted-by":"crossref","unstructured":"Costa M, Furness JB, Cuello ACU, Verhofstad AA, Steinbusch HWM, and Elde RP (1982) Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their visualization and reactions to drug treatment. Neuroscience 7: 351\u2013363.","DOI":"10.1016\/0306-4522(82)90272-X"},{"key":"10.1124\/jpet.107.123729_bib7","doi-asserted-by":"crossref","unstructured":"Croci T and Bianchetti A (1992) Stimulation of faecal excretion in rats by \u03b12adrenergic antagonists. J Pharm Pharmacol 44: 358\u2013360.","DOI":"10.1111\/j.2042-7158.1992.tb03621.x"},{"key":"10.1124\/jpet.107.123729_bib8","doi-asserted-by":"crossref","unstructured":"Dietrich C and Kilbinger H (1996) 5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanism. Neuropharmacology 35: 483\u2013488.","DOI":"10.1016\/0028-3908(95)00197-2"},{"key":"10.1124\/jpet.107.123729_bib9","doi-asserted-by":"crossref","unstructured":"Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE Janssens J, Funch-Jensen P, Corazziari E, Richter JE, et al. (1993) U.S. householder survey of functional gastrointestinal disorders: prevalence, sociode-mography, and health impact. Digest Dis Sci 38: 1569\u20131580.","DOI":"10.1007\/BF01303162"},{"key":"10.1124\/jpet.107.123729_bib10","unstructured":"Filip M, Baran L, Siwanowicz J, Chojnacka-Wojcik E, and Przegalinski E (1992) The anxiolytic-like effects of 5-hydroxytryptamine3 (5-HT3) receptor antagonists. Pol J Pharmacol Pharm 44: 261\u2013269."},{"key":"10.1124\/jpet.107.123729_bib11","doi-asserted-by":"crossref","unstructured":"Foreman MM, Fuller RW, Leander JD, Benvenga MJ, Wong DT, Nelson DL, Calligaro DO, Swanson SP, Lucot JB, and Flaugh ME (1993) Preclinical studies on LY228729: a potent and selective serotonin1A agonist. J Pharmacol Exp Ther 267: 58\u201371.","DOI":"10.1016\/S0022-3565(25)39565-0"},{"key":"10.1124\/jpet.107.123729_bib12","unstructured":"Fozard JR and Host M (1982) Selective inhibition of the Bezold-Jarisch effect of 5-HT in the rat by antagonists at neuronal 5-HT receptors. Br J Pharmacol 77: 520P"},{"key":"10.1124\/jpet.107.123729_bib13","doi-asserted-by":"crossref","unstructured":"Friedman G (1991) Treatment of the irritable bowel syndrome. Gastroenterol Clin North Am 20: 325\u2013333.","DOI":"10.1016\/S0889-8553(21)00554-9"},{"key":"10.1124\/jpet.107.123729_bib14","doi-asserted-by":"crossref","unstructured":"Galligan JJ (1992) Differential inhibition of cholinergic and noncholinergic neurogenic contractions by 5-hydroxytryptamine1A receptor agonists in guinea pig ileum. J Pharmacol Exp Ther 260: 306\u2013312.","DOI":"10.1016\/S0022-3565(25)11232-9"},{"key":"10.1124\/jpet.107.123729_bib15","doi-asserted-by":"crossref","unstructured":"Galligan JJ, Surprenant A, Tonini M, and North RA (1988) Differential localization of 5-HT1 receptors on myenteric and submucosal neurons. Am J Physiol 255: G603\u2013G611.","DOI":"10.1152\/ajpgi.1988.255.5.G603"},{"key":"10.1124\/jpet.107.123729_bib16","doi-asserted-by":"crossref","unstructured":"Gordon JA and Hen R (2004) The serotonergic system and anxiety. Neuromolecular Med 5: 27\u201340.","DOI":"10.1385\/NMM:5:1:027"},{"key":"10.1124\/jpet.107.123729_bib17","doi-asserted-by":"crossref","unstructured":"Gore S, Giolmore IT, Haigh CG, Brownless SM, Stockdale H, and Morris AL (1990) Colonic transit in man is slowed by ondansetron(GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 4: 139\u2013144.","DOI":"10.1111\/j.1365-2036.1990.tb00458.x"},{"key":"10.1124\/jpet.107.123729_bib18","doi-asserted-by":"crossref","unstructured":"Kim DY and Camilleri M (2000) Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2698\u20132709.","DOI":"10.1111\/j.1572-0241.2000.03177.x"},{"key":"10.1124\/jpet.107.123729_bib19","unstructured":"Kimura M, Sakata T, Nakagawa T, Fukamachi K, Ago Y, Tamai H, Mine K, Tachibana S, and Takayama T (1992) Clinical evaluation of tandospirone (SM-3997), on psychosomatic diseases with gastrointestinal complaints. Clin Eval 20: 225\u2013257."},{"key":"10.1124\/jpet.107.123729_bib20","doi-asserted-by":"crossref","unstructured":"Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, and Carter E (2001) Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96: 2662\u20132670.","DOI":"10.1111\/j.1572-0241.2001.04128.x"},{"key":"10.1124\/jpet.107.123729_bib21","doi-asserted-by":"crossref","unstructured":"Lucki I (1992) 5-HT1 receptors and behavior. Neurosci Biobehav Rev 16: 83\u201393.","DOI":"10.1016\/S0149-7634(05)80055-7"},{"key":"10.1124\/jpet.107.123729_bib22","doi-asserted-by":"crossref","unstructured":"Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, and Shemer A (1992) Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol 12: 341\u2013345.","DOI":"10.1097\/00004714-199210000-00009"},{"key":"10.1124\/jpet.107.123729_bib23","doi-asserted-by":"crossref","unstructured":"Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, Tsutsumi R, Katsuyama Y, and Honda K (1992) Role of the serotonin3 receptor in stress-induced defecation. J Pharmacol Exp Ther 261: 297\u2013303.","DOI":"10.1016\/S0022-3565(25)10975-0"},{"key":"10.1124\/jpet.107.123729_bib24","doi-asserted-by":"crossref","unstructured":"O\u2019Connell MT, Sarna GS, and Curzon G (1992) Evidence for post-synaptic mediation of the hypothermic effect of 5-HT1A receptor activation. Br J Pharmacol 106: 603\u2013609.","DOI":"10.1111\/j.1476-5381.1992.tb14382.x"},{"key":"10.1124\/jpet.107.123729_bib25","doi-asserted-by":"crossref","unstructured":"Paintal AS (1973) Vagal sensory receptors and their reflex effects. Physiol Rev 53: 159\u2013227.","DOI":"10.1152\/physrev.1973.53.1.159"},{"key":"10.1124\/jpet.107.123729_bib26","doi-asserted-by":"crossref","unstructured":"Prior A and Read NW (1993) Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 7: 175\u2013180.","DOI":"10.1111\/j.1365-2036.1993.tb00087.x"},{"key":"10.1124\/jpet.107.123729_bib27","unstructured":"Robinson DS (1991) Buspirone in the treatment of anxiety, in Buspirone: Mechanisms and Clinical Aspects (Tunnicliff G, Eision AS, and Taylor DP eds) pp 3\u201317, Academic Press, Inc, San Diego, CA."},{"key":"10.1124\/jpet.107.123729_bib28","unstructured":"Roychoudhury M and Kulkarni SK (1997) Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. Methods Find Exp Clin Pharmacol 19: 107\u2013111."},{"key":"10.1124\/jpet.107.123729_bib29","unstructured":"Sasa M (1997) A new approach to innovating selective anxiolytics. Jpn J Psychopharmacol 17: 53\u201359."},{"key":"10.1124\/jpet.107.123729_bib30","unstructured":"Sharma HS and Day PK (1981) Impairment of blood-brain barrier (BBB) in rats by immobilization stress: role of serotonin (5-HT). Ind J Physiol Pharmacol 25: 111\u2013122."},{"key":"10.1124\/jpet.107.123729_bib31","doi-asserted-by":"crossref","unstructured":"Stanton JA and Beer MS (1997) Characterization of a cloned human 5-HT1A receptor cell line using [35S]GTP\u03b3S binding. Eur J Pharmacol 320: 267\u2013275.","DOI":"10.1016\/S0014-2999(96)00914-4"},{"key":"10.1124\/jpet.107.123729_bib32","doi-asserted-by":"crossref","unstructured":"Talley NJ (2001) Serotoninergic neuroenteric modulators. Lancet 358: 2061\u20132068.","DOI":"10.1016\/S0140-6736(01)07103-3"},{"key":"10.1124\/jpet.107.123729_bib33","doi-asserted-by":"crossref","unstructured":"Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, MacCarty RL, and Ciociola A (1990) GR38032F(ondansetron), a selective 5-HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 35: 477\u2013480.","DOI":"10.1007\/BF01536922"},{"key":"10.1124\/jpet.107.123729_bib34","doi-asserted-by":"crossref","unstructured":"Talley NJ, Zinsmeister AR, Van Dyke C, and Melton LJ (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101: 927\u2013934.","DOI":"10.1016\/0016-5085(91)90717-Y"},{"key":"10.1124\/jpet.107.123729_bib35","doi-asserted-by":"crossref","unstructured":"Traber J and Glaser T (1987) 5-HT1A receptor-related anxiolytics. Trends Pharmacol Sci 8: 432\u2013437.","DOI":"10.1016\/0165-6147(87)90231-8"},{"key":"10.1124\/jpet.107.123729_bib36","doi-asserted-by":"crossref","unstructured":"Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, and Thomforde GM (1992) Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 102: 102\u2013108.","DOI":"10.1016\/0016-5085(92)91789-7"},{"key":"10.1124\/jpet.107.123729_bib37","doi-asserted-by":"crossref","unstructured":"Whitehead WE and Crowell MD (1991) Psychologic considerations in the irritable bowel syndrome. Gastroenterol Clin North Am 20: 249\u2013267.","DOI":"10.1016\/S0889-8553(21)00549-5"},{"key":"10.1124\/jpet.107.123729_bib38","doi-asserted-by":"crossref","unstructured":"Williams CL, Villar RG, Peterson JM, and Burks TF (1988) Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology 94: 611\u2013621.","DOI":"10.1016\/0016-5085(88)90231-4"},{"key":"10.1124\/jpet.107.123729_bib39","doi-asserted-by":"crossref","unstructured":"Yamamoto O, Niida H, Tajima K, Shirouchi Y, Kyotani Y, Ueda F, Kise M, and Kimura K (1998) Effect of YNS-15P, a new alpha-2 adrenoceptor antagonist, on stress-stimulated colonic propulsion in rats. J Pharmacol Exp Ther 287: 691\u2013696.","DOI":"10.1016\/S0022-3565(24)37845-0"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.123729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:23:59Z","timestamp":1739985839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524340716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0022356524340716"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.123729","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Properties of 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3 H)-one (TZB-30878), a Novel Therapeutic Agent for Diarrhea-Predominant Irritable Bowel Syndrome (IBS) and Its Effects on an Experimental IBS Model","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.123729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}